DrStockPick.com Stock Report!

Monday September 14, 2009

**************************************************************

Blue Square-Israel Ltd. (NYSE: BSI) announced that it was served with a claim and a request for approval as a class action (the “Claim”), in which Blue Square is being sued regarding the sale of cosmetics and perfume products without marking the expiry date or the allowed use period after its opening, as is allegedly obligatory according to the 15 amendment of the Pharmacists directive [new edition] 1981 which is in effect since July 1st 2009.

InferX Corporation (Pink Sheets: NFRX) today announced that it has signed a Memoradum of Understanding (MOU) with KG Information Systems

...

DrStockPick.com Stock Report!

Friday September 11, 2009

**************************************************************

JAG Media Holdings, Inc. (OTC Bulletin Board: JAGH) has entered into an agreement with The Investor Relations Group, Inc. (”IRG”), pursuant to which IRG will provide various investor relations and public relations services for the Company in accordance with the terms of the agreement. As of Tuesday, September 15th, all stockholders should address any inquiries directly to IRG.

DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage pharmaceutical company, today announced that it has entered into a definitive agreement with several institutional investors to sell 6,578,947 units, with each unit consisting of one of the Company’s common shares

...

Yesterday, AstraZeneca Plc (AZN) announced that Crestor, its cholesterol-lowering drug (statin) reduced the risk of heart attacks, strokes, artery-clearing procedures and death in elderly patients. The results from the JUPITER study (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin), showed that Crestor 20mg reduced major cardiovascular events. The administration of the drug to a sub-set of 5,695 patients aged 70 years or above reduced the risk of cardiovascular events by 39% compared to placebo. The study also revealed that Crestor reduced the risk of heart attack as well as stroke by 45% each in 17,802 patients (the total population of the study). The results were presented at the European Society of Cardiology (ESC) meeting in Barcelona, Spain. Results from the randomized, double-blind, placebo-controlled study were initially presented in November 2008. We feel that the analysis from the JUPITER ...

AstraZeneca (AZN) recently said that results from a phase III head-to-head trial showed that its Brilinta (ticagrelor) achieved greater efficacy in the primary endpoint, reduction of cardiovascular events, compared to Sanofi-Aventis/Bristol-Myers’ (SNY/BMY) Plavix (clopidogrel).

Brilinta significantly reduced the mortality rate from cardiovascular events, myocardial infarctions and strokes without increasing major bleeding, which is a side-effect of Plavix. However, the frequently reported side-effects of Brilinta included slower heart rhythms and dyspnoea.

Brilinta is an investigational oral anti-platelet treatment being developed for acute coronary syndrome (ACS). Results from the 18,624 patient PLATO (A Study of Platelet Inhibition and Patient Outcomes) trial were presented at the European Society of Cardiology congress and published in the New England Journal of Medicine (NEJM).

The data on Brilinta look compelling and could help the product gain market share from Plavix once launched. Sanofi-Aventis recorded 2.6 billion Euros from Plavix sales last year,

...

Highlights include AstraZeneca plc (AZN), Bristol-Myers Squibb Company (BMY), Sanofi-Aventis SA (SNY) and Eli Lilly and Company (LLY).Brilinta Not AstraZeneca's PanaceaThis morning, AstraZeneca (AZN) announced positive top-line results of its phase III 18,600-patient PLATO trial, comparing AZN's Brilinta (ticagrelor) with Plavix (clopidogrel) in the reduction of cardiovascular events in patients with acute coronary syndrome (i.e. - at-risk of cardiovascular events).The company announced that Brilinta met the primary endpoint in the trial, a statistically significant difference in time to occurrence of any event of the composite endpoint of myocardial infarction, stroke or cardiovascular death. Safety was comparable to what was observed in phase II trials.The full-results of the trial are expected to be presented at the annual European Society of Cardiology meeting in August. AstraZeneca expects to submit Brilinta for FDA approval in the fourth quarter 2009, potentially ...